Clinical Trial Update: A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

View source ↗

Summary

A Phase 4 randomized trial comparing FF/UMEC/VI single-inhaler triple therapy to Budesonide/Formoterol plus Tiotropium in COPD; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/Formoterol (budesonide/formoterol)
• Fluticasone Furoate/ Umeclidinium/ Vilanterol
• tiotropium (tiotropium)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Pulmonary Disease, Chronic Obstructive | Phase 4 | Status: COMPLETED | Results posted: 2020-02-12